Voya Investment Management LLC Sells 12,101 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Voya Investment Management LLC reduced its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 20.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 47,613 shares of the specialty pharmaceutical company’s stock after selling 12,101 shares during the period. Voya Investment Management LLC owned 0.08% of Supernus Pharmaceuticals worth $2,275,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in Supernus Pharmaceuticals by 8.8% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,375 shares of the specialty pharmaceutical company’s stock worth $453,000 after acquiring an additional 1,161 shares in the last quarter. CWM LLC raised its position in shares of Supernus Pharmaceuticals by 92.4% during the second quarter. CWM LLC now owns 3,080 shares of the specialty pharmaceutical company’s stock worth $97,000 after purchasing an additional 1,479 shares during the period. Meritage Portfolio Management lifted its holdings in shares of Supernus Pharmaceuticals by 2.7% in the 2nd quarter. Meritage Portfolio Management now owns 60,398 shares of the specialty pharmaceutical company’s stock worth $1,904,000 after purchasing an additional 1,595 shares in the last quarter. Envestnet Asset Management Inc. grew its position in Supernus Pharmaceuticals by 50.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 90,525 shares of the specialty pharmaceutical company’s stock valued at $2,853,000 after purchasing an additional 30,256 shares during the period. Finally, QRG Capital Management Inc. increased its stake in Supernus Pharmaceuticals by 7.4% during the 2nd quarter. QRG Capital Management Inc. now owns 18,892 shares of the specialty pharmaceutical company’s stock valued at $595,000 after purchasing an additional 1,309 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on SUPN shares. Stifel Nicolaus raised their price objective on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research note on Friday, December 19th. Cantor Fitzgerald upped their target price on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an “overweight” rating in a report on Tuesday, September 30th. Bank of America assumed coverage on Supernus Pharmaceuticals in a research note on Wednesday, October 29th. They set a “buy” rating and a $65.00 price target for the company. Zacks Research downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 8th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, December 22nd. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $61.60.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN opened at $51.57 on Monday. The business’s fifty day moving average is $48.50 and its 200-day moving average is $43.17. The stock has a market capitalization of $2.96 billion, a price-to-earnings ratio of -151.67, a PEG ratio of 0.62 and a beta of 0.72. Supernus Pharmaceuticals, Inc. has a one year low of $29.16 and a one year high of $57.65.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). The company had revenue of $170.00 million for the quarter, compared to analysts’ expectations of $175.82 million. Supernus Pharmaceuticals had a positive return on equity of 11.51% and a negative net margin of 2.81%.The business’s quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter last year, the business posted $0.69 EPS. Research analysts expect that Supernus Pharmaceuticals, Inc. will post 2.38 EPS for the current fiscal year.

Insider Buying and Selling

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 59,900 shares of the business’s stock in a transaction on Thursday, October 9th. The stock was sold at an average price of $50.57, for a total value of $3,029,143.00. Following the sale, the chief executive officer directly owned 1,206,578 shares in the company, valued at $61,016,649.46. The trade was a 4.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Padmanabh P. Bhatt sold 710 shares of the stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $44.44, for a total value of $31,552.40. Following the transaction, the vice president owned 14,508 shares of the company’s stock, valued at $644,735.52. The trade was a 4.67% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 80,610 shares of company stock valued at $4,068,895. 8.80% of the stock is owned by company insiders.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.